Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
INO 
Inovio Pharmaceuticals Inc (INO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: INO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $7.47
1 Year Target Price $7.47
| 2 | Strong Buy |
| 1 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -19.62% | Avg. Invested days 20 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 86.09M USD | Price to earnings Ratio - | 1Y Target Price 7.47 |
Price to earnings Ratio - | 1Y Target Price 7.47 | ||
Volume (30-day avg) 5 | Beta 1.39 | 52 Weeks Range 1.30 - 8.01 | Updated Date 08/14/2025 |
52 Weeks Range 1.30 - 8.01 | Updated Date 08/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.59 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -52568.65% |
Management Effectiveness
Return on Assets (TTM) -59.3% | Return on Equity (TTM) -140.12% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 53451291 | Price to Sales(TTM) 472.15 |
Enterprise Value 53451291 | Price to Sales(TTM) 472.15 | ||
Enterprise Value to Revenue 293.15 | Enterprise Value to EBITDA -1.09 | Shares Outstanding 50960200 | Shares Floating 49387069 |
Shares Outstanding 50960200 | Shares Floating 49387069 | ||
Percent Insiders 0.51 | Percent Institutions 20.29 |
Upturn AI SWOT
Inovio Pharmaceuticals Inc
Company Overview
History and Background
Inovio Pharmaceuticals Inc., founded in 1979 as Genetronics Biomedical Corporation and later renamed Inovio in 2003, is a biotechnology company focused on developing and commercializing DNA medicines to treat and prevent diseases. It has evolved from initially focusing on electroporation devices to developing DNA-based immunotherapies and vaccines.
Core Business Areas
- DNA Medicines: Developing and testing DNA medicines for infectious diseases, cancer, and other diseases using its proprietary CELLECTRA delivery system.
Leadership and Structure
Dr. Joseph Kim is the President and CEO. The company has a board of directors overseeing strategic direction and management.
Top Products and Market Share
Key Offerings
- VGX-3100 (Cervical Dysplasia): A DNA medicine being developed for the treatment of HPV-related cervical dysplasia. The drug is still under development with the competitive landscape made of drugs from companies such as Merck & Co. and Roche Holding AG.
- INO-4800 (COVID-19 Vaccine): A DNA vaccine candidate developed for the prevention of COVID-19. Clinical trials were conducted. Market is dominated by Pfizer/BioNTech and Moderna.
Market Dynamics
Industry Overview
The biotechnology industry is highly competitive and rapidly evolving, with significant investments in research and development. It faces regulatory hurdles and long development timelines.
Positioning
Inovio focuses on DNA medicines and delivery technology. Its competitive advantage lies in its CELLECTRA delivery system and its approach to developing novel therapies, but it faces challenges in clinical development and commercialization.
Total Addressable Market (TAM)
The total addressable market (TAM) for DNA-based therapies and vaccines is substantial, with potential in infectious diseases and cancer. Exact figures are hard to pinpoint but itu2019s estimated to be in the tens of billions of dollars globally. Inovio's market position is speculative, and future adoption will depend on successful clinical trials and regulatory approvals.
Upturn SWOT Analysis
Strengths
- Proprietary CELLECTRA delivery system
- Diverse pipeline of DNA medicine candidates
- Experience in DNA vaccine development
Weaknesses
- History of clinical trial setbacks and delays
- Limited commercial success to date
- High cash burn rate and dependence on external funding
Opportunities
- Potential to develop breakthrough DNA medicines for unmet medical needs
- Partnerships with larger pharmaceutical companies for development and commercialization
- Expansion of CELLECTRA technology into new therapeutic areas
Threats
- Competition from established pharmaceutical companies and other biotechnology firms
- Regulatory hurdles and clinical trial failures
- Negative perception of DNA medicines due to past failures in the field
Competitors and Market Share
Key Competitors
- MRNA
- PFE
- JNJ
Competitive Landscape
Inovio faces intense competition from larger pharmaceutical companies with greater resources and established market presence. Its competitive advantage relies on its DNA medicine technology and its ability to address unmet medical needs.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been largely driven by spikes related to vaccine candidates, followed by subsequent declines due to clinical trial results or market changes.
Future Projections: Future growth is dependent on successful clinical trial outcomes and regulatory approvals for its DNA medicine candidates. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include advancing clinical trials for VGX-3100, securing partnerships, and seeking funding for research and development.
Summary
Inovio Pharmaceuticals has promising DNA medicine technology, but its financial struggles, clinical trial setbacks, and the competitive landscape make it a risky investment. The company shows promise with its pipeline but needs to address its high cash burn and produce conclusive results. Investor confidence in the company will depend on delivering positive clinical trial results in the future. Inovio must be nimble and innovative to survive.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
- Market Research Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a financial professional. Market share estimates are approximate and may vary depending on the source.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Inovio Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Plymouth Meeting, PA, United States | ||
IPO Launch date 1998-02-12 | CEO, President & Director Dr. Jacqueline E. Shea Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 134 | Website https://www.inovio.com |
Full time employees 134 | Website https://www.inovio.com | ||
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the University of Pennsylvania, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter BioLogics, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.